GEMM

Kibur Medical Presents a Rational Approach to Identify Novel Combinations as Potential Immuno-oncology Therapies at the American Academy of Cancer Research in Orlando, FL

Retrieved on: 
Thursday, April 6, 2023
Charles River Laboratories, AACR, Kidney cancer, CDX, Syngenic, GEMM, Annual International Exhibition, Booth, American Academy, Gordon Mills, PDX, Spatial analysis, Oregon Health Plan, Brigham, Drug combination, Northwestern Health Sciences University, Poster, Hospital, FDA, Tumor microenvironment, Oregon Health & Science University, Breast cancer, Pharmaceutical industry

BOSTON, April 6, 2023 /PRNewswire-PRWeb/ -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present two posters at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing immune-oncology applications of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.

Key Points: 
  • Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies.
  • The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.
  • "This work furthers our mission to transform cancer care and advance precision medicine for better patient outcomes."
  • Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Syngenic, Immune system, NSCLC, Congress, Non-small-cell lung carcinoma, Glioblastoma, RCC, RNA, Cancer, IND, Large-cell lung carcinoma, SCLC, Renal cell carcinoma, Squamous cell carcinoma, Patient, Melanoma, Burn, SVV, Annual report, EGFR, Workforce, Genome, Wilms' tumor, Senecavirus, Nature Communications, Security (finance), GEMM, Mouse, HCC, Hepatocellular carcinoma, IV, RNA transfection, CVA21, Immunotherapy, Investment, Safety, Vaccine, Pharmaceutical industry, PDX, LNP

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022

Retrieved on: 
Tuesday, October 18, 2022
CET, Therapy, Population, Acute myeloid leukemia, AML, Squamous cell carcinoma, ENA, Neoplasm, Patient, American Association for Cancer Research, Molecule, Hepatocellular carcinoma, Research, HCC, Sarcoma, Metastasis, Cancer Prevention and Research Institute of Texas, C57BL/6J, GEMM, Research institute, SCI, Treatment, Mouse, National Cancer Institute, AACR, NSCLC, European Organisation for Research and Treatment of Cancer, Cancer research, American Association, Toxicity, CEO, EORTC, Transducin, Cancer prevention, Osteosarcoma, Lymphoma, Literature, Homeostasis, Death, Cell membrane, NCI, Large-cell lung carcinoma, Pharmaceutical industry, Medical imaging, Cancer

HOUSTON, Oct. 18, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, announced that results from a preclinical murine study of tegavivint in beta-catenin activated hepatocellular carcinoma (HCC) will be featured in a poster presentation and discussion session at the 34th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium (ENA 2022). ENA 2022 is being held October 26-28, 2022, in Barcelona, Spain.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types, including HCC.
  • Up to 50% of HCC patients have tumors driven by activating beta-catenin and canonical Wnt pathway mutations.
  • Additionally, in mice with established tumors, tegavivint treatment increased CD3+ T-lymphocyte tumor infiltration, with prominent increases in intratumoral CD8+ T-cells.
  • Iterion is currently advancing multiple clinical programs investigating tegavivint in cancer indications where nuclear beta-catenin overexpression is a known factor.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Retrieved on: 
Friday, October 7, 2022
SVV, U.S. Securities and Exchange Commission, RNA transfection, HSV, Renal cell carcinoma, Transgene, Therapy, Syngenic, SEC, Investor, IND, Virus, Neoplasm, Annual report, Patient, IV, Hepatocellular carcinoma, RNA, Security (finance), Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SCLC, Nasdaq, GEMM, Cancer, Private Securities Litigation Reform Act, Mouse, Immune system, Company, Large-cell lung carcinoma, Research, Safety, GLOBE, Melanoma, Nature Communications, CVA21, FDA, COVID-19, LNP, Risk, Vaccine, PDX, Senecavirus, Young LNP

The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.

Key Points: 
  • The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.
  • By encapsulating vRNA in LNPs, Oncorus was able to recapitulate oncolytic viral therapy in various tumor cells and avoid neutralizing antibodies.
  • The vRNA/LNP constructs were well tolerated and elicited tumor-specific in situ production of oncolytic virions, immune cell recruitment and tumor destruction.
  • Overall, synthetic RNA viruses were well tolerated after a single or multiple IV dose in mice and non-human primates.

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
RCC, Private Securities Litigation Reform Act, PDX, Therapy, Degenerative disease, Investor, Orthornavirae, IND, AACR, Risk, Immunotherapy, Tropism, American Association, Neoplasm, Cancer, Mark (given name), RNA, U.S. Securities and Exchange Commission, NSCLC, Renal cell carcinoma, Food, Security (finance), Genome, Immune system, Association, American Association for Cancer Research, Safety, RNA transfection, Transgene, CDX, HSV, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Melanoma, Myelocyte, SVV, Senecavirus, CVA21, Wilms' tumor, LNP, Annual report, FDA, Potyvirus, PD-L1, GEMM, Patient, Large-cell lung carcinoma, IV, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced its presentation of preclinical data for both ONCR-021 and ONCR-788 in two e-posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana, supporting the company’s selectively self-amplifying viral RNA (vRNA) Immunotherapy Platform.

Key Points: 
  • The preclinical data presented on ONCR-021 and ONCR-788 at AACR are an important step forward for Oncorus novel approach of selectively self-amplifying vRNA immunotherapies formulated in lipid nanoparticles.
  • Oncorus vRNA Immunotherapy Platform encapsulates the genomes of RNA viruses known to kill cancer cells within an LNP, producing a living oncolytic and immunostimulatory viral infection in the tumor to destroy cancer cells and stimulate the immune system.
  • In preclinical studies, Oncorus IV-administered vRNA immunotherapies demonstrated efficacy in multiple tumor models, avoiding the challenges seen in previous studies incorporating IV administration of RNA-based oncology therapeutics.
  • Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity.

Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022

Retrieved on: 
Wednesday, April 6, 2022
Technology, Research, Other Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, MIF, Leadership, Tumor microenvironment, AACR, Research, Pathology, American Association, ISP, Cancer, Precision medicine, RNA, Neoplasm, AstraZeneca, 2021 Essex County Council election, Industry, Association, American Association for Cancer Research, Workflow, Solution, Titan Mare Explorer, GEMM, Bayer, Merck, Medical imaging, Takeda, Fluidigm

The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME.

Key Points: 
  • The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME.
  • Ultivue will also host their 2nd annual Biomarker Insights Summit on April 8th, 2022, ahead of the annual AACR meeting.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.
  • Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research.

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

Retrieved on: 
Wednesday, November 17, 2021
Carbon, Gastrointestinal tract, CEO, Safety, Bariatric surgery, Cell, CFU-GEMM, Company, Bacteria, Irritable bowel syndrome, Chronic kidney disease, Urine, SAN, ID, GI, Kidney failure, Therapy, Hyperoxaluria, Inflammatory bowel disease, Kidney, CFU, Risk, GLOBE, Metabolic disorder, Adult, Conditional sentence, Absorption, FDA, Kidney stone disease, GEMM, Prevalence, Disease, CKD, Pharmaceutical industry, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability to safely colonize the human gut with a therapeutically engineered microbe and control its abundance via once-daily dosing of a prebiotic control molecule. Based on these results, Novome intends to commence a Phase 2a study to evaluate preliminary efficacy in patients with enteric hyperoxaluria.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers.
  • Based on these results, Novome intends to commence a Phase 2a study to evaluate preliminary efficacy in patients with enteric hyperoxaluria.
  • This groundbreaking study validates Novomes approach to controllably and safely engraft a therapeutically engineered microbe into the human gut.
  • In the Phase 1 study, the dose of NB2000P was modified within adaptive groups to tune the abundance of NB1000S in the gut.

Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer

Retrieved on: 
Wednesday, October 20, 2021
Eaton Partners, Bank of America, Risk, BBA, SPAC, J. P. Morgan, MBA, GEMM, Ulcerative colitis, Chicago (franchise), SAN, Thomas Weisel Partners, Research, Leadership, Irritable bowel syndrome, GLOBE, Stifel, McLeod, Patient, University, Bacteria, Methodist University, Industry, Equity capital markets, Conditional sentence, Southern Methodist University, Kidney, Bank, Therapy, Company, Pharmaceutical industry, Management

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today announced the appointment of Bill McLeod as Chief Financial Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today announced the appointment of Bill McLeod as Chief Financial Officer.
  • His track record in public and private capital raising speaks for itselfdecades of investment banking transactions that have supported the development of numerous companies R&D through commercial activities, said Blake Wise, Chief Executive Officer of Novome Biotechnologies.
  • Novome Biotechnologies, Inc. is a clinical-stage biotechnology company developing engineered cellular therapies for the gut to treat chronic diseases.
  • For more information, please visit the Novome Biotechnologies website at https://novomebio.com/

AMD Announces Ambitious Goal to Increase Energy Efficiency of Processors Running AI Training and High Performance Computing Applications 30x by 2025

Retrieved on: 
Wednesday, September 29, 2021
Goal, FP16, CTO, Research, GEMM, Efficiency, ESG, Memory, NASDAQ, AMD EPYC, AMD, Artificial intelligence, PUE, AI, High Performance Computing Modernization Program, Instinct, Benchmarking, Twitter, CEO, Genomics, Total, Supercomputer, HPC, IDC, Central processing unit, Advanced Micro Devices, Hyperion, Facebook, CPU, BF16, GPU, Drug discovery, TEC, Electricity, Blog, EPYC, Name, Industry, GLOBE, Cryptocurrency, Video game console, Renewable energy

With computing becoming ubiquitous from edge to core to cloud, AMD has taken a bold position on the energy efficiency of its processors, this time for the accelerated compute for AI andHigh Performance Computing applications, said Addison Snell, CEO of Intersect360 Research.

Key Points: 
  • With computing becoming ubiquitous from edge to core to cloud, AMD has taken a bold position on the energy efficiency of its processors, this time for the accelerated compute for AI andHigh Performance Computing applications, said Addison Snell, CEO of Intersect360 Research.
  • Dr. Jonathan Koomey, President, Koomey Analytics, said The energy efficiency goal set by AMD for accelerated compute nodes used for AI training and High Performance Computing fully reflects modern workloads, representative operating behaviors and accurate benchmarking methodology.
  • 1 Includes AMD high performance CPU and GPU accelerators used for AI training and High-Performance Computing in a 4-Accelerator, CPU hosted configuration.
  • 2 Based on 2015-2020 industry trends in energy efficiency gains and data center energy consumption in 2025.